We demonstrate the mechanism by which C3G, a major dietary anthocyanin, regulates energy metabolism and insulin sensitivity. Oral administration of C3G reduced hepatic and plasma triglyceride levels, adiposity, and improved glucose tolerance in mice fed high-fat diet. Hepatic metabolomic analysis revealed that C3G shifted metabolite profiles towards fatty acid oxidation and ketogenesis. C3G increased glucose uptake in HepG2 cells and C2C12 myotubes and induced the rate of hepatic fatty acid oxidation. C3G directly interacted with and activated PPARs, with the highest affinity for PPARα. The ability of C3G to reduce plasma and hepatic triglycerides, glucose tolerance, and adiposity and to induce oxygen consumption and energy expenditure was abrogated in PPARα-deficient mice, suggesting that PPARα is the major target for C3G. These findings demonstrate that the dietary anthocyanin C3G activates PPARs, a master regulators of energy metabolism. C3G is an agonistic ligand of PPARs and stimulates fuel preference to fat.
Cyanidin-3-O-glucoside (C3G) is a major flavonoid anthocyanin in plant-based foods, such as leafy vegetables, berries, red cabbages, teas, and coloured grains\textsuperscript{13,14}. Epidemiologic studies have suggested that the dietary intake of anthocyanidins prevents dyslipidaemia, cardiovascular disease, and type 2 diabetes\textsuperscript{15,16}. However, the mechanism of action and target proteins of C3G are not clearly understood.

In plants, C3G is an important secondary metabolite with a multitude of biological functions, including UV protection, pathogen defence, insect attraction, symbiosis, and flower variation\textsuperscript{17,18}. Plant food containing C3G that is ingested by humans undergoes digestion in the gut, following which both C3G and its aglycone, cyanidin, can be absorbed by the intestinal epithelium and delivered to the circulation to exert multiple biological functions in tissues\textsuperscript{19}. C3G is more stable than its aglycone cyanidin in aqueous solution\textsuperscript{20,21}; thus, C3G is believed to be the major bioavailable and active form of cyanidin in human tissues.

Natural small molecules and dietary compounds often exert several biological activities. For example, salicylate, an ancient drug that was originally identified in willow tree bark, carries out multiple biological activities including exerts anti-inflammatory activity\textsuperscript{22,23}, reducing hepatic glucose production and lowering adiposity\textsuperscript{24}. Short-chain fatty acids interact with at least three G-protein coupled receptors, FFAR2, FFAR3, and the ectopic olfactory receptor OR51E2\textsuperscript{16,17} to have several effects in mice and humans. Likewise, a number of in vitro and in vivo studies reported several biological activities of C3G\textsuperscript{18–20}; however, none of these studies have clearly reported the molecular mechanism of action and direct molecular targets of C3G.

Peroxisome-proliferator activated receptors (PPARs) are nuclear receptors and ligand-activated transcription factors that regulates several biological pathways including cellular energy metabolism and inflammation\textsuperscript{21}. Three PPARs, \(\alpha\), \(\gamma\), and \(\delta\) isoforms have unique tissue distributions and biological activities. PPAR\(\alpha\) is widely expressed in different tissues with high expression levels in liver and skeletal muscle that regulates the expression of genes encoding enzymes and transport proteins that control lipid homeostasis and thus stimulates fatty acid oxidation and improves lipoprotein metabolism\textsuperscript{22,23}. In addition, PPAR\(\alpha\) has been suggested to play a major role in the regulation of hepatic lipid oxidation and to serve as a distinctive marker of the brown fat phenotype, which is involved in transcriptional control of PGC-1\(\alpha\) in brown adipose tissue, thereby maintaining energy homeostasis\textsuperscript{24}. PPAR\(\alpha\) agonists, fibrates, are used to treat hypertriglyceridaemia. PPAR\(\gamma\) is expressed in several tissues with high expression levels in white adipose tissue and has been known to regulate adipocyte differentiation, fatty acid storage, and glucose metabolism\textsuperscript{25}. PPAR\(\gamma\) activation improves insulin resistance by opposing the effect of TNF\(\alpha\) in adipocytes\textsuperscript{26}. PPAR\(\gamma\) enhances the expression of a number of genes encoding proteins involved in glucose and lipid metabolism\textsuperscript{27}. Thus, PPAR\(\gamma\) agonists, thiazolidinediones, are used as prescribed drugs for the treatment of type 2 diabetes.

It has been shown that C3G could increase gene expressions of PPAR\(\gamma\)-\(\alpha\)-\(\delta\) in mice fed a high-fat diet (HFD). The oral administration of C3G to mice for 8 weeks significantly reduced plasma and hepatic triglyceride (TG) concentrations (\(P<0.05\) and \(P<0.01\), respectively); C3G reduced the number of intracellular lipid droplets, and F4/80 levels in C3G-HFD livers, suggesting that C3G improves non-alcoholic fatty liver disease (NAFLD) (Fig. 1a, b). Intracellular TG concentrations were also reduced in HepG2 cells stimulated with C3G compared to control HepG2 cells (Fig. 1c). GW7647, a PPAR\(\alpha\) agonist, reduced intracellular triglyceride levels and fatty acid oxidation rate but increased fatty acid synthesis rate in lipid-loaded HepG2 cells. Total cholesterol, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol concentrations were unaltered by C3G administration in mice (Supplementary Fig. 1a). By analysing hepatic fatty acid metabolic rates, C3G was shown to stimulate the rate of fatty acid oxidation but suppress the rate of fatty acid synthesis in both HepG2 cells and mouse livers (Fig. 1d, e).

The oral administration of C3G had an antiobesogenic effect on mice, as indicated by reduced body weight, visceral fat tissue weight, adipocyte size, the ratio of white-to-brown adipose tissues and the increased ratio of white adipose tissue-to-skeletal muscle weight in HFD mice administered C3G (Fig. 1f, g, Supplementary Fig. 1b, and Supplementary Table 1). Aortic atherosclerotic plaque formation was decreased in mice administered C3G with a HFD (Supplementary Fig. 1c).

The oral administration of C3G improved key parameters indicating insulin sensitivity in mice. C3G decreased fasting plasma glucose and insulin concentrations and increased adiponectin concentrations without affecting liver glycogen and FGF21 levels (Fig. 2a–c). C3G also improved glucose and insulin tolerance, HOMA-IR, and the insulin sensitivity index in mice fed a HFD (Fig. 2d–f). To investigate glucose uptake upon treatment with C3G, we induced insulin resistance in cultured C2C12 myotubes and HepG2 cells by treating them with 400 \(\mu\)M lipids for 24 h and then measured their glucose uptake. Insulin promoted glucose uptake in C2C12 myotubes and HepG2 cells that were not lipid-loaded. C3G improved the impaired glucose uptake in lipid-loaded C2C12 myoblasts and HepG2 cells (Fig. 2g). These results collectively demonstrate that C3G improved NAFLD, adiposity, glucose tolerance, hyperglycaemia, and insulin sensitivity in mice fed a HFD.

C3G alters the hepatic fatty acid oxidation metabolites. We next examined the hepatic metabolomes of fasting mice by CE-MS and GC-TOF-MS and by assay kits. HFD-fed mice were orally administered either vehicle (saline) or C3G for 8 weeks, and the liver metabolome was analysed in mouse livers in a fasting state. CE-MS and GC-TOF-MS analyses identified 92 metabolites (selected key metabolites are shown in Table 1 and Supplementary Table 1). Multivariate statistical analysis was conducted to determine the significance of any differences in the metabolomes of liver tissues from mice fed different diets for 8 weeks. By using partial least squares regression (PLSR) analysis, the metabolite profiles of each group were distinctively clustered. These findings suggest that C3G caused unique and specific alterations in the mouse liver metabolome (Fig. 3a).

C3G reduced fasting plasma glucose concentrations (Fig. 2a) but increased the levels of metabolites in the first phase of glycolysis including glucose 6-phosphate and fructose 6-phosphate (Table 1). These results suggest that C3G elevated hepatic glucose uptake by metabolic trapping. C3G indeed increased glucose uptake in HepG2 cell and C2C12 myotubes (Fig. 2g). Although fructose 1,6-biphosphate, a product of phosphofructokinase-1, was unaltered, the levels of metabolites in the second phase of glycolysis including pyruvic acid and lactic acid levels were substantially reduced in the C3G group (Table 1), which suggest decreased rate of glycolysis by C3G was
acetyl CoA levels were unaltered, but the level of citrate was dramatically reduced and nearly undetectable in the C3G group compared with the controls (Table 1). Citrate, the first metabolite in the citric acid cycle, is an activator of the anabolic pathway and an inhibitor of the catabolic pathway of fatty acid and glucose metabolism. The concentration of malonyl-CoA, an inhibitor of mitochondrial fatty acid oxidation, was reduced substantially following C3G administration (Fig. 2b). Furthermore, the level of β-hydroxybutyrate was substantially increased by C3G (Fig. 3b). By immunoblotting, pyruvate dehydrogenase kinase 4 (PDK4) expression and PDK4-mediated phosphorylation of pyruvate dehydrogenase complex (PDH, pSer232E1α subunit) were increased by C3G administration (Fig. 3c). Glycerol 3-phosphate was increased in C3G-treated livers (Table 1). Glycerol 3-phosphate can be produced from dihydroxyacetone phosphate by glycerol 3-phosphate dehydrogenase or from the transported lipolyzed glycerol in adipose tissue. These results suggest that C3G suppressed fatty acid synthesis but increased catabolic pathways including fatty acid oxidation, ketogenesis, and at least in part increased lipolysis in white adipose tissues.

The levels of carnitine and its related metabolites choline and betaine aldehyde were increased in the livers of C3G-treated mice compared with those of control mice (Table 1). Carnitine is critical in mitochondrial fatty acid transport and subsequent fatty acid oxidation; thus, increased levels in the blood after carnitine administration have been shown to reduce body weight and body mass index. Thus, elevated levels of carnitine metabolites could contribute to increase fatty acid oxidation and body fat reduction. The levels of α-ketoglutarate, fumarate, and malic acid were reduced but succinate levels were increased in the C3G group compared with the control group (Table 1).

In addition, C3G increased the levels of amino acids, particularly, branched amino acids, compared with those
HFD-fed control mice (Supplementary Table 2). These findings indicate that C3G induces cellular protein degradation pathways, such as autophagy. Branched amino acids have diverse roles and it has been reported that branched chain amino acid could protect hepatic steatosis and NAFLD, thus increased branched chain amino acids may reinforce improvement of NAFLD in mice.

The level of reduced glutathione (GSH) and the ratio of reduced GSH to oxidized GSSH were decreased in the livers of C3G-treated mice (Table 1), which implies that C3G increased antioxidant capacity in the liver. As above mentioned, C3G increased glucose 6-phosphate conversion to 6-phosphogluconate in pentose phosphate pathway. NADPH produced from pentose phosphate pathway may be mildly increased, and the produced NADPH may be utilized to increase GSH levels antioxidant capacity in the liver.

The results of the metabolomic analysis collectively indicated that hepatic glucose uptake was increased by C3G and that conversion of glucose 6-phosphate to the pentose phosphate pathway or other pathways was increased. Most importantly, C3G stimulates catabolic energy metabolism including hepatic fatty acid oxidation, ketogenesis, and possibly white adipose lipolysis, which indicates a shifting energy metabolism towards the fat-consuming mode.

C3G binds and activates PPARs. C3G activates PPARs, as it has been reported that C3G induces PPAR gene expression and has hypolipidaemic and antiobesogenic effects. C3G also ameliorated hypertriglyceridaemia and NAFLD and increased the rate of fatty acid oxidation (Fig. 1). Hepatic metabolomic analysis suggested induction of fatty acid oxidation and ketogenesis by C3G, with decreased malonyl-CoA and citrate levels (Table 1 and Fig. 4a). These phenotypic and metabolomic profiles suggested PPAR activation. Accordingly, we investigated whether C3G is a ligand of PPARs. First, the interaction of C3G with the ligand-binding domain (LBD) of PPARs was quantified with coactivator recruitment assays. GW7647, troglitazone, and GW0742 were PPARα, -γ, and -δ/β agonists and the agonist interacted with the PPAR isomers, respectively. C3G was found to interact with the LBD of three PPAR isomers and exhibited the highest binding affinity for PPARα. The EC50 values of C3G were 1.1, 10.8, and 31.1 μM for the PPARα, -γ, and -δ/β subtypes, respectively (Fig. 4a and Supplementary Table 3). Second, surface plasmon resonance experiments demonstrated that C3G directly interacted with three PPAR subtypes and exhibited the highest binding affinity for PPARα (Supplementary Fig. 2a and Supplementary Table 3). By qPCR analysis, the mRNA expression of PPARα and its target genes, Acox and Ucp2, was shown to be induced in the mouse livers of C3G group (Fig. 4b). Two additional dietary anthocyanins-pelargonidin—3-O-glucoside and delphinidin—3-O-glucoside—were also shown to interact directly with PPAR LBDs

Fig. 2 C3G improves glucose and insulin tolerance in mice. a Fasting glucose and insulin levels. b, c Fasting adiponectin, hepatic FGF12, and hepatic glycogen levels in mice. d Oral glucose tolerance test. e Intraperitoneal insulin tolerance test. f Insulin sensitivity indices. g Glucose uptake. LL lipid-loading.

\*P < 0.05, \**P < 0.01, and ++\**P < 0.005 compared with controls.
responsive genes, 
Acox1
adipose tissue weight, mRNA expression levels of the PPAR
COMMUNICATIONS BIOLOGY |           (2020) 3:514 | https://doi.org/10.1038/s42003-020-01231-6 | www.nature.com/commsbio

–
Fig. 2b). These results demonstrate that agonistic PPARs and exhibits the highest affinity for the PPARα subtype of PPARs. To the best of our knowledge, this study is the first to describe a direct interaction between C3G and PPARs. Results showed that PPARγ gene expression was also induced by C3G. However, whether C3G activates PPARα alone or induces both PPARα and -γ, the metabolic effects of C3G were abrogated in PPARα KO mice, which demonstrate activation of PPARα is a key for C3G activity. PPARγ activation, if occurs by C3G in vivo, may reinforce the metabolic effects. The binding affinity of PPARγ to C3G is ~10 times weaker than the affinity to PPARα as demonstrated in TR-FRET and SPR experiments in our study. These results collectively demonstrated that PPARα may be a primary target protein of the metabolic effects of C3G (Fig. 7).

Dietary C3G is absorbed by glucose transporters in the intestinal epithelium and delivered to the circulation to carry out bodies in the liver were also nullified in PPARα-deficient mice (Fig. 5b–f and Supplementary Table 4). These results demonstrated that the hypolipidaemic, hypoglycaemic, and antiobesogenic effects of C3G are primarily dependent on PPARα activation.

C3G reduces adiposity with increases energy expenditure. Metabolome analysis revealed increased oxidative metabolism induced by C3G. C3G also reduced adiposity in HFD-fed mice, and the antiobesogenic mechanism of C3G was further investigated in mice. C3G administration for 8 weeks reduced visceral adipose tissue and adipocyte size, while the reduction in white adipose tissues induced by C3G was abolished in PPARα-deficient mice. Cells in the brown adipose tissue of HFD-fed mice administered C3G were smaller (Fig. 6a), and the mRNA expression levels of PPARs, PGC-1α and UCP1 in brown adipose tissue were higher; however, these C3G-induced changes were not observed in PPARα-deficient mice (Fig. 6b). Activation of the PPARα-PGC-1α-UCP1 signalling axis by C3G in brown adipose tissue increased oxygen consumption and energy expenditure and caused adiposity in vivo.

Table 1 Major liver metabolites from mice fed a HFD and C3G for 8 weeks using CE-MS and GC-TOF-MS.

| Metabolites                         | CE-MS relative peak area (mean ± SD) | HFDb  | C3Gc  |
|-------------------------------------|--------------------------------------|-------|-------|
| Glucose 6-phosphate                 | 25.445 ± 0.567                       | 29.021 ± 0.610* |
| Fructose 6-phosphate                | 8.591 ± 0.176                        | 10.051 ± 0.273* |
| Fructose 1,6-diphosphate            | 0.653 ± 0.067                        | 0.635 ± 0.100  |
| Dihyridoxacetic phosphate           | 8.268 ± 0.338                        | 11.394 ± 0.098* |
| 3-Phosphoglyceric acid              | 70.567 ± 1.293                       | 41.054 ± 0.929* |
| 2-Phosphoglyceric acid              | 7.936 ± 0.195                        | 4.822 ± 0.314  |
| Phosphoethanolpyruvic acid          | 17.362 ± 0.732                       | 10.277 ± 0.095* |
| Pyruvic acid                        | 54.875 ± 1.452                       | 30.684 ± 2.973* |
| Lactic acid                         | 10140.602 ± 101.363                  | 9024.705 ± 350.355* |
| Fructose 1-phosphate                | 11944 ± 0.776                        | 13448 ± 0.737*  |
| Glyceraldehyde 3-phosphate          | 230.470 ± 6.285                      | 779.513 ± 25.265* |
| 2,3-Diphosphoglyceric acid         | 4.747 ± 0.057                        | 4.099 ± 0.024  |

TCAs cycle:
- Acetyl CoA: 0.032 ± 0.013
- CoA: 0.412 ± 0.012
- Citric acid: 3.995 ± 0.455
- 2-Hydroxyglutaric acid: 12.884 ± 0.588
- Succinic acid: 62.239 ± 1.267
- Fumaric acid: 700.874 ± 9.309
- Malic acid: 2106.790 ± 28.503
- TCA cycle: 1795.026 ± 79.442

Glutathione metabolism:
- Glutathione (GSH): 57.658 ± 3.408
- Glutathione (GSSG): 1633.081 ± 35.013
- S-Acetylhomocysteine: 10.261 ± 0.219
- Cystathionine: 35.019 ± 1.206
- Homocysteine: 3.362 ± 0.725
- Threonine: 4798.134 ± 132.978
- Carnitine and choline metabolism:
- Carnitine: 30.006 ± 5.024
- Choline: 2150.539 ± 113.030
- Betaine aldehyde: 413.371 ± 8.955
- Betaine: 764.813 ± 8.778
- Folic acid: 0.238 ± 0.022

1*P < 0.05.
2*Values are the means of three replicates for the peak area relative to the internal standard = standard deviation (SD).
3*High-fat diet 45%.
4*High-fat diet 45% + cyanidin-3-O-p-D-glucoside oral administration.

by surface plasmon resonance experiments (Supplementary Fig. 2b). These results demonstrate that agonistic PPARα and -γ activity is not limited to C3G but extends to other anthocyanins; thus, pelargonidin-3-O-glucoside and delphinidin-3-O-glucoside may exert hypolipidaemic and antiobesogenic effects similar to those of C3G.

In addition, the gene expression of PPARγ and its target genes are also induced in HepG2 and C2C12 myotubes (Supplementary Fig. 3). Previous pharmacokinetic studies reported that the Cmax of C3G is 0.14–14 μM11,36–38, suggesting that dietary C3G activates the PPARα and PPARγ subtypes in vivo. These results demonstrate that PPARα may be a major and direct target protein of C3G during its regulation of hyperlipidaemia and insulin resistance and it is also possible that C3G also activates PPARγ, which further contributes to the improvement of lipid and glucose metabolism.

Next, we performed feeding studies in PPARα-deficient mice orally administered C3G for 8 weeks. Reductions in plasma TG and fasting glucose concentrations were completely abrogated in PPARα-deficient mice (Fig. 5a). Changes in the rates of fatty acid synthesis and oxidation, body weight, fat mass, white-to-brown adipose tissue weight, mRNA expression levels of the PPARα responsive genes, Acox1 and Ucp2, malonyl-CoA, and ketone
biological activities in different tissues, including the liver, skeletal muscle, and adipose tissue. Membrane transport of C3G in humans has not been clearly elucidated; however, the cellular uptake of anthocyanins, including C3G, is reduced by inhibitors of bilitranslocase, glucose transporters, breast cancer resistance protein, and multidrug resistance-1, which suggests that multiple transporters with broad substrate specificity may be involved in anthocyanin uptake. In aqueous solution, C3G is more stable than cyanidin aglycone in aqueous solution; thus, C3G is the major bioavailable form of cyanidin in the circulation. However, most of the biological effects of cyanidin have been studied using cyanidin aglycone rather than C3G. The levels of C3G in plasma and different tissues were vary from 0.14 to 14 µM depending on the amount of oral intake, type of analysis methods, and animal models. Isotope labeled C3G feeding studies showed bioavailability of C3G is approximately 12.4%. Consumption of a 500 mg oral bolus dose of 13C-labelled C3G showed that Cmax was 0.14 and 0.334 µM in plasma and urine, respectively. On the other hand, a pharmacokinetic study of anthocyanin-rich extract from wild mulberry, composed
of 79% of C3G, showed that $C_{\text{max}}$ was 5.7 μg/mL (11.8 μM) in plasma. More recently, in a study by Chen Y et al., oral gavage of 50 mg/kg of C3G in SD rats showed that $C_{\text{max}}$ of C3G was 14 μM at 45 min. In a systematic review by Sandoval et al. reported that anthocyanin concentrations in tissues are 6–217 ng/g tissue weight in different tissues of several animal models and authors concluded that anthocyanin such as C3G may have an important role in human health at this concentration range.

These reports are in-line with our findings that C3G in physiological conditions may exert potent biological activity as a PPARα ligand. Although the plasma levels and tissue levels of C3G is low but it should not be ruled out that local concentration as C3G (e.g. in nucleus or in cytosol) may be high enough to activate PPARα and this possibility should be studied in the future.

Human pharmacokinetic studies have shown that the relative bioavailability of C3G in humans was ~12.4%, the maximum serum concentration was 5.97 μM at 10.25 h, and the half-life ranged between 12.44 and 51.62 h when 500 mg of isotopically labelled C3G was consumed. We measured the EC50 of C3G for PPARα (1.1 μM) in this study, and the results indicate that circulating C3G can sufficiently activate PPARα. Cyanidin aglycone is a PPARα agonist that reduces lipid accumulation in cultured hepatocytes; however, C3G is more stable in aqueous solution and has an EC50 value lower than that reported for cyanidin aglycone, and C3G is the major cyanidin form found in the citrus fruit

and has an EC50 value lower than that reported for cyanidin aglycone, and C3G is the major cyanidin form found in the circulation after cyanidin intake; thus, C3G is an effective natural substance that activates PPARα. PPARα activation has metabolic benefits. Thus, potent PPARα agonists, fibrate, have been used to treat hyperlipidaemia, but these agents have side effects including stomach pain and liver problems. However, C3G, a natural substance with a relatively moderate PPARα-binding affinity, may be used to treat or prevent hypertriglyceridaemia. In cultured cells, it is possible that C3G induced PPARα as well, thus we do not rule out the possibility that C3G activates PPARγ in vivo as well. C3G is metabolized quickly after intestinal absorption; however, studies found that the concentration of C3G is substantially high in vivo.

In the metabolomic analysis, C3G increased metabolites in the first phase of glycolysis (glucose 6-phosphate, fructose 6-phosphate, dihydroxyacetone phosphate) but reduced metabolites in the second phase of glycolysis (3-phosphoglyceric acid, 2-phosphoglyceric acid, phosphoenolpyruvic acid, pyruvic acid) as well as lactic acid, a surrogate marker for glycolysis activity. These findings suggest that C3G may increase glucose uptake but reduced glycolysis activity. C3G also reduces levels of metabolites in citric acid cycle (with an exception of succinate) including citric acid, an allosteric activator for anabolism. These findings suggest that C3G suppressed anabolic metabolism, which was
C3G

Ligand activation

PPARα

TG (liver, plasma)
NAFLD
Adiposity
Glucose/Insulin Tolerance

Fig. 7 Mechanism by which C3G regulates lipid and glucose metabolism. C3G directly interacts with PPARs with the highest affinity to PPARα to increase hepatic fatty acid oxidation and reduce fatty acid synthesis. These effects lead to reduced plasma and hepatic TG concentrations, with increased ketogenesis, improves NAFLD, glucose and insulin tolerance and adiposity.

In addition, the levels of 6-phosphogluconate was increased but not ribose 5-phosphate and ribose 1-phosphate, which are surrogate markers of ribulose 5-phosphate, a final product in the oxidative phase of pentose phosphate pathway. These suggest that C3G only mildly increase conversion of glucose 6-phosphate to pentose phosphate pathway. pentose phosphate increases NADPH production. NADP is a reducing power required in biosynthetic pathways but also is important in several other metabolism including glutathione metabolism. In our results, the level of reduced glutathione (GSH) was increased but oxidized form (GSSG) was decreased. Thus, it is possible that NADPH produced from pentose phosphate pathway may be consumed to maintain cellular oxidative capacity of liver increasing the levels of GSH.

Increased phosphorylation of PDH by PDK4, increased ketogenic body levels and dramatically reduced hepatic citrate and malonyl-CoA levels suggested that C3G stimulated fatty acid oxidation. Citrate is an activator of lipid synthesis while malonyl-CoA inhibits CPR-1 to suppress acyl transport to mitochondrial matrix in fatty acid. PDH is an enzyme that converts pyruvate to acetyl CoA, and its activity is largely inhibited by PDK447. pSer293E1α subunit of PDH is the most rapidly phosphorylated site by PDKs including PDK4 and PDH inhibition by PDK4 increases acetyl CoA flux to the citric acid cycle from fatty acid oxidation while confirmed by reduced fatty acid synthesis rates measured in livers of mice and HepG2 hepatocytes.
pressing production of acetyl CoA from pyruvate and glycolysis, thus reducing fat accumulation in extra-adipose tissue, ameliorating lipotoxicity, and improving insulin resistance. Branched-chain amino acids are functional amino acids that can directly converted into energy fuels and are known to improve muscle functions. Although the significance of hepatic branched-chain amino acids is not clear yet, there is a study that reported protective role of branched chain amino acids in the prevention of NAFLD/NASH and we suggest that increased branched chain amino acids in the mouse liver may further contribute to the improved NAFLD by C3G.

The changes in betaine, choline, and carnitine levels in liver tissues following C3G administration demonstrated that C3G activates fatty acid oxidation and decreases plasma and hepatic TG levels. C3G reduced lipid accumulation in brown adipose tissue, with induction of oxygen consumption and energy expenditure measured by indirect calorimetry. These metabolic alterations could be the result of PPAR activation; however, these effects were negated in PPARα-deficient mice. These findings suggest that PPARα is a major target protein for C3G in the regulation of energy metabolism.

In conclusion, in this study, we demonstrate that the molecular targets of the small molecule C3G are PPARs and that C3G induces glucose and fatty acid catabolism to improve glucose tolerance and hepatic steatosis in HFD-fed mice. Increased thermogenic gene expression in brown adipose tissue, and increased energy expenditure collectively caused the metabolic alterations induced by C3G.

Methods

Materials and reagents. Commercially available materials and reagents are listed in Supplementary Table 5.

Cell culture and mouse experiments. HepG2 cells and HEK293 cells were obtained from the Korean Cell Line Bank (Seoul, Korea) and cultured and maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% foetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 °C with a humidified atmosphere of 5% CO2. Stock of C3G and fenofibrate were prepared in dD2O and DMSO, respectively, and used for the treatment of the cells. HepG2 cells were seeded at a density of 10^6 cells/well in 6-well plates for 24 h and then cells were lipid-loaded with free fatty acids (400 μM of palmitic acid and 400 μM of oleic acid) with 0.5% bovine serum albumin (GenDEPOT, TX, USA) for 24 h. Lipid-loaded cells were then treated with C3G (10 and 50 μM) or GW7647 (1 μM) as the positive control for lipid analysis. For mouse experiments, C57BL/6J male mice were purchased from Samitako Co. (Kyunggido, Korea), and PPARα-deficient mice were purchased from Taconic (Hudson, NY, USA). Male mice were used in the experiments. C57BL/6J and PPARα-deficient mice were maintained under a 12-h light/12-h dark cycle at a temperature of 21–25 °C and a relative humidity of 50–60% and fed with a purchased 45% HFD (45% of calories from fats; Central Lab. Animal Inc., Seoul, Korea) for 4 weeks. Then, the mice were randomly assigned to two groups: HFD-fed with vehicle (PBS) and HFD-fed with oral administration of C3G (50 mg/kg body weight) for an additional 8 weeks. Body weight was assessed weekly. At the end of the experimental period, the mice were fasted for 12 h and sacrificed. Blood was collected in EDTA tubes (BD Biosciences, CA, USA) retro-orbitally by cardiac puncture, centrifuged for 30 min at 2000 rpm at 4 °C to collect plasma samples, and stored at −80 °C. The organs, including the liver, brown adipose tissues, and white adipose tissues (epididymal, visceral, and perirenal fat), were collected and snap-frozen in liquid nitrogen and then stored at −80 °C for further use. All animal experiments were performed according to a protocol approved by the Animal Experiment Committee of Korea University (Protocol No. KUAUCUC-20090420-4).

Metabolomic analysis. Sample preparation and detailed methods for CE-MS and GC-TOF-MS are presented in the Supplementary Methods.

Statistics and reproducibility. All of the data are shown as the means ± SEMs, and one-way analysis of variance (ANOVA) was used to calculate the significance of the difference between each set of two groups. A value of P < 0.05 was considered significant. Statistical analysis was performed with GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, CA, USA). For metabolomic analysis, ANOVA was performed using SPSS (Version 12.0, Chicago, IL, USA) to assess statistically significant differences in metabolites in plasma samples from mice fed C3G with a HFD. Duncan’s multirange test was used when the level of significance was set at P < 0.05. Multivariate statistical analyses, such as principal component analysis (PCA) and PLSR, were performed with SIMCA-P+ (Version 11.0 Umetrics, Umeå, Sweden). PCA and PLSR were used to distinguish different diets on the basis of the content of metabolites in samples and to explore the correlations between metabolites and obesity-related biochemical parameters.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. Source data underlying plots shown in figures are available in Supplementary Data 1. Full blots are shown in Supplementary Information. Additional data related to this paper are available from the corresponding author on reasonable request.

Received: 26 November 2019; Accepted: 2 July 2020; Published online: 18 September 2020

References

1. Olivas-Aguirre, F. J. et al. Cyanidin-3-O-glucoside: physical-chemistry, foodomics and health effects. Molecules 21, 1264 (2016).
2. Deng, G. F. et al. Phenolic compounds and bioactivities of pigmented rice. Crit. Rev. Food Sci. Nutr. 53, 296–306 (2013).
3. Yang, L. et al. Effects of anthocyanins on cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. Adv. Nutr. 8, 693–697 (2017).
4. van Dam, R. M., Naidoo, N. & Landberg, R. Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: review of recent findings. Curr. Opin. Lipidol. 24, 25–33 (2013).
5. Kimble, R., Keane, K. M., Lodge, J. K. & Howatson, G. Dietary intake of anthocyanins and risk of cardiovascular disease: a systematic review and meta-analysis of prospective cohort studies. Crit. Rev. Food Sci. Nutr. 59, 1–12 (2018).
6. Guo, X., Yang, B., Tan, J., Jiang, J. & Li, D. Associations of dietary intakes of anthocyanins and flavonanes and risk of cardiovascular disease in men. Am. J. Clin. Nutr. 104, 587–594 (2016).
7. Winkel-Shirley, B. Flavonoid biosynthesis. A colorful model for genetics, biochemistry, cell biology, and biotechnology. Plant Physiol. 126, 485–493 (2001).
8. Zhao, J. & Dixon, R. A. The ‘ins’ and ‘outs’ of flavonoid transport. Trends Plant Sci. 15, 72–80 (2010).
9. Czank, C. et al. Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a (13)C-tracer study. Am. J. Clin. Nutr. 97, 995–1003 (2013).
10. Rakic, V. P. et al. Effects of P value on the stability of cyanidin and cyanidin 3-O-beta-glucopyranoside in aqueous solution. Hemisphaerica Industria 69, 511–522 (2015).
11. Higgs, G. A., Moncada, S. & Vane, J. R. Eicosanoids in inflammation. Ann. Clin. Res. 16, 287–299 (1984).
12. Yuan, M. et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikbeta. Science 293, 1673–1677 (2001).
13. Hawley, S. A. et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336, 918–922 (2012).
14. Kimura, I., Ichimura, A., Ohue-Kitano, R. & Igarashi, M. Free fatty acid receptors in health and disease. Physiol. Rev. 100, 171–210 (2019).
15. Eisenberg, W. H. et al. Defining an olfactory receptor function in airway smooth muscle cells. Sci. Rep. 6, 38231 (2016).
16. Khoo, H. E., Azlan, A., Tang, S. T. & Lim, S. M. Anthocyanidins and anthocyanins: colored pigments as food, pharmaceutical ingredients, and the potential health benefits. Food Nutr. Rev. 61, 1361779 (2017).
17. Rozanska, D. & Regulski-Row, B. The significance of anthocyanins in the prevention and treatment of type 2 diabetes. Adv. Clin. Exp. Med. 27, 135–142 (2018).
18. Zhang, J. et al. Neuroprotective effects of anthocyanins and its major component cyanidin-3-O-glucoside (C3G) in the central nervous system: An outlined review. Eur. J. Pharmacol. 858, 172500 (2019).
19. Fan, W. & Evans, R. PPARs and ERs: molecular mediators of mitochondrial metabolism. Curr. Opin. Cell Biol. 33, 49–54 (2015).
20. Hondoires, E. et al. Peroxisome proliferator-activated receptor alpha (PPARalpha) induces PPARgamma coactivator 1alpha (PGC-1alpha) gene
expression and contributes to thermogenic activation of brown fat: involvement of PPARα. J. Biol. Chem. 286, 43112–43122 (2011).

23. Huiska, A., Marangi, M., Matžkainen, N. & Taskinen, M. R. PPARγ: an emerging therapeutic target in diabetic microvascular disease. Nat. Rev. Endocrinol. 6, 453–463 (2010).

24. Jeremic, N., Chaturvedi, P. & Tyagi, S. C. Browning of white fat: novel insights into factors, mechanisms, and therapeutic targets. J. Cell Physiol. 232, 61–68 (2017).

25. Sandoval-Ramirez, B. A. et al. Anthocyanin tissue bioavailability in animals: the bad and the future. Nat. Med. 19, 557–566 (2013).

26. Moller, D. E. & Berger, J. P. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int. J. Obes. Relat. Metab. Disord. 27 (Suppl 3), S17–S21 (2003).

27. Yamazaki, T., Shirasati, S., Kishimoto, K., Miura, S. & Etsaki, O. An increase in liver PPARgamma2 is an initial event to induce fatty liver in response to a diet high in butter: PPARgamma2 knockdown improves fatty liver induced by high-saturated fat. J. Nutr. Biochem. 22, 543–553 (2011).

28. Saccozzio, B. et al. Cyanidin-3-O-beta-glucoside and protocatechuic acid exert insulin-like effects by upregulating PPARgamma activity in human omental adipocytes. Diabetes 60, 2334–2244 (2011).

29. Takashina, Y., Manabe, A., Tabuchi, Y. & Kari, A. Cyanidin increases the expression of Mg2+-transport carriers mediated by the activation of PPARalpha in colonic epithelial MCE301 cells. Nutrients 11, 641 (2019).

30. Chypre, M., Zaidi, N. & Smans, K. ATP-citrate lyase: a mini-review. Drug Metab. Rev. 42, 1–4 (2012).

31. Salie, M. J. & Thelen, J. J. Regulation and structure of the heteromeric acetyl-CoA carboxylase. Biochim. Biophys. Acta 1861, 1207–1213 (2016).

32. Festuccia, W. T. et al. Control of glyceroneogenic activity in rat brown adipose tissue. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R177–R182 (2003).

33. Pooyandjob, M., Nouchi, M., Shab-Bidar, S., Djalilian, K. & Olyaeemanesh, A. The effect of (L)-carnitine on weight loss in adults: a systematic review and meta-analysis of randomized, controlled trials. Obes. Rev. 17, 970–976 (2016).

34. Honda, T. et al. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. Metabolism 69, 177–187 (2017).

35. Tutunchi, H., Ostadahimi, A., Saghafi-Asl, M. & Maleki, V. The effects of oleoylthanolamide, an endogenous PPAR-alpha agonist, on risk factors for NAFLD: a systematic review. Obes. Rev. 20, 1057–1069 (2019).

36. de Ferrars, R. M. et al. The pharmacokinetics of anthocyanins and their metabolites in humans. Br. J. Pharmacol. 171, 3268–3282 (2014)

37. Hassimotto, N. M., Genovese, M. I. & Lajolo, F. M. Absorption and metabolism of cyanidin-3-glucoside and cyanidin-3-rutinoside extracted from wild mulberry (Morus nigra L.) in rats. J. Agric. Food Chem. 56, 6356–6361 (2008).

38. Passamonti, S., Vrhovsek, U. & Mattivi, F. The interaction of anthocyanins with bilitranslocase. Biochem. Biophys. Res. Commun. 296, 631–636 (2002).

39. Faria, A. et al. Absorption of anthocyanins through intestinal epithelial cells—putative involvement of GLUT2. Mol. Nutr. Food Res. 53, 1430–1437 (2009).

40. Dreiseitel, A. et al. Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br. J. Pharmacol. 158, 1942–1950 (2009).

41. Fang, J. Bioavailability of anthocyanins. Drug Metab. Rev. 46, 508–520 (2014).

42. Festuccia, W. T. et al. Control of glyceroneogenic activity in rat brown adipose tissue. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R177–R182 (2003).

43. Honda, T. et al. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. Metabolism 69, 177–187 (2017).

44. Wright, M. B., Bortolini, M., Tadayyon, M. & Bopst, M. Minireview: challenges and opportunities in development of PPAR agonists. Mol. Endocrinol. 28, 1756–1768 (2014).

45. Jia, Y. et al. Cyanidin is an agonistic ligand for peroxisome proliferator-activated receptor-alpha reducing hepatic lipid. Biochim. Biophys. Acta 1831, 698–708 (2013).

Acknowledgements

This work was supported by a National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT) (Grant Nos. NRF-2018R1A4A1022589 and NRF-2019R1A2C3005227), and the ‘Cooperative Research Program for Agriculture Science & Technology Development (Project No. PJ0112530218)’, Rural Development Administration (RDA), Republic of Korea. This research was supported by the School of Life Sciences and Biotechnology for BK21 PLUS, Korea University.

Author contributions

S.J.L. conceived the study; Y.J., C.W., and Y.S.K. designed experiments; S.O.Y. and M.Y.S. performed and interpreted ligand activity assays. Y.J., C.W., Y.S.K., S.O.Y., Y.E.Y., and M.Y.J. performed animal experiments; Y.J. and T.H.P. performed fatty acid oxidation experiments; J.S.K. and M.Y.J. performed glucose uptake analysis; Y.J., C.W., Y.S.K., S.O.Y., Y.E.Y., and S.J.L. wrote the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s42003-020-01231-6.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020